Clinical trials: Cancer of Thorax
Non-small Cell Lung Cancer Stage III
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy…
- Trial name
- NCT02412371
- Testing
- Paclitaxel, Carboplatin, Veliparib
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than…
- Trial name
- NCT01160744
- Testing
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6)
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Advanced/Metastatic Solid Tumors, Bladder Cancer
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07090499
- Testing
- PF-08046876, Pembrolizumab, Cisplatin
- Where
- 31 sites in United States, Canada and 4 more
- Volunteers
- 540 people
- Sponsor
- Pfizer
NSCLC, Stage I, II, IIIA, IIIB
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
To explore the efficacy and safety of ensartinib on adjuvant therapy guided by MRD in IA3-IIIB (T3N2) stage ALK-positive non-small cell lung cancer patients.
- Trial name
- NCT06780839
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cancer Pain, Lung Cancer
A Hospital Based Survey on Lung Cancer Related-pain in Northern China
This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer…
- Trial name
- NCT03189277
- Volunteers
- 2,000 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung
NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy
Relapses after perioperative chemotherapy and surgery
- Trial name
- NCT00535275
- Testing
- Chemotherapy with platine, Chemotherapy without Cisplatine
- Where
- 78 sites in France
- Volunteers
- 88 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer, Nonsmall Cell
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
REFINE-lung will test whether reduced pembrolizumab dose frequency after 6 months of standard treatment is safe and effective. Patients treated with 1st line pembrolizumab who are progression free and otherwise planning to…
- Trial name
- REFINE-Lung (NCT05085028)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 37 sites in United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- Imperial College London
Stage IIIA Non-small Cell Lung Cancer
PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC
A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT07043907
- Testing
- PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy
- Volunteers
- 115 people
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
Pulmonary Neoplasm
Robot-assisted vs VATS Lobectomy for NSCLC
Robot-assisted thoracoscopic surgery (RATS) was widely used in thoracic surgery, the surgical safety and feasibility of RATS lobectomy for NSCLC has been confirmed.
- Trial name
- RVlob (NCT03134534)
- Testing
- VATS lobectomy, RATS lobectomy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.
- Trial name
- NCT01828112
- Testing
- Ceritinib, Pemetrexed, Docetaxel
- Where
- 97 sites in United States, Belgium and 18 more
- Volunteers
- 231 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Lung Cancer
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US).
- Trial name
- NCT02847728
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 1,189 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping
The primary objective of the CLIPPCAIR study is to construct and validate a new algorithm for predicting post-operative forced expiratory volume in 1 second (FEV1) values for lung resection candidates; this new model will be…
- Trial name
- CLIPPCAIR (NCT03885765)
- Testing
- Predictive data, Lung resection
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Lung Cancer
To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of…
- Trial name
- NCT05432128
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Singlera Genomics Inc.
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
- Trial name
- NCT02482311
- Testing
- AZD 1775
- Where
- 16 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Lung Cancer
Manchester Lung Health Study
The Manchester Lung Health Study (qUEST) will assess the uptake of a community-based lung cancer screening service and its impact across a deprived area of North and East Manchester, which has high rates of lung cancer.
- Trial name
- qUEST (NCT04409444)
- Testing
- Lung Cancer Screening, Biomarkers
- Where
- United Kingdom
- Volunteers
- 9,730 people
- Sponsor
- Manchester University NHS Foundation Trust
Non-small Cell Lung Cancer
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
This is a prospective, single arm, single center clinical study to determine the efficacy and safety of pablizumab combined with apatinib and neoadjuvant chemotherapy in patients with stage iia-iiia non-small cell lung cancer.
- Trial name
- NCT04968002
- Testing
- pablizumab combined with apatinib and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer, Lung Cancer
Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester
The EMBRaCE-GM study is a multi-cohort trial designed to efficiently evaluate the range of wearable vital signs monitors that could be used to support patients during cancer treatment.
- Conditions
- Colorectal Cancer, Lung Cancer, Hematological Cancer, CAR T-Cell Therapy
- Trial name
- EMBRaCE-GM (NCT05099237)
- Testing
- OURA Ring, WithingsScan Watch, Isansys Patient Status Engine
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Manchester University NHS Foundation Trust
Lung Cancer
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
As a single agent, paclitaxel has a response rate of 33% and 25-29% in SCLC patients with sensitive relapse and with resistant relapse, respectively.
- Trial name
- NCT00453167
- Testing
- Paclitaxel, Gemcitabine
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Korea